Moonfare

Yes. AltStreet completed Moonfare's documented onboarding flow including investor questionnaire, accreditation verification, and biometric ID verification through Moonfare's contracted third-party KYC provider. We followed the published 'Complete your profile' procedure for data room access. We received no response to the data access request. The account was briefly blocked after engagement with the public catalog and subsequently unblocked. Data room access did not unlock as the platform's documentation describes. This is a single verified user-access test, not proof that no verified investor receives data-room access — but it is falsifiable evidence that the documented procedure does not always resolve as published. No capital was committed and no investment was made — the test was specifically to verify whether Moonfare's documented onboarding-to-disclosure flow delivers as published. It did not in this test. Any prospective investor can replicate the verification by completing the same KYC procedure and requesting data room access for their own account.

Three-layer fee stack: (1) Moonfare 0.50% one-time placement fee on commitments, structurally confirmed across 11+ catalog records with identical verbatim language; (2) Moonfare annual feeder fee — Series Fund I LLC tiers range from 0.35% to 0.75% depending on share class plus annual liability compensation to feeder GP of 0.025%; (3) Underlying GP fund economics — typically 1.5-2.0% management fee on committed capital declining to invested capital, plus 20% carried interest over an 8% hurdle. Cumulative impact on net IRR is meaningful over 10-12 year fund lifetimes. The catalog tile typically displays only the underlying GP target returns; the Moonfare layer is structurally additive.

Moonfare positions the 'Complete your profile' data room as the gateway to substantive fund information — PPMs, Key Information Documents, detailed performance history, fee schedules, and underlying GP investor materials. The public catalog tiles display only marketing summaries, forward targets, and methodology footnotes. AltStreet completed accreditation verification, investor questionnaire, and biometric ID verification through Moonfare's contracted provider. The data room did not unlock after profile completion in this verified test. The account was briefly blocked after catalog engagement and subsequently unblocked. No substantive fund documents became accessible through the procedure Moonfare documents. This is a single verified user-access test, not proof that no verified investor receives data-room access — but it is falsifiable evidence that the documented procedure does not always resolve as published. The implication for prospective investors: validate independently that the data room actually resolves for your account before committing capital.

Two findings are tied for most material. First: material predecessor fund underperformance buried in dense methodology footnotes. HIG Europe Middle Market LBO Fund I (Feeder A28) footnote 3 verbatim states 'The net returns for HIG Europe Capital Partners II reflecting its actual management fee of 2.5% are 1.0x MOIC and 0.6% IRR.' The immediate predecessor to the fund being marketed returned LPs essentially nothing — effectively catastrophic for LP return expectations on that prior vintage, with headline showing forward target 25-30% gross IRR. Ares COF VI (Feeder A27) shows the same pattern with ACOF V at 0.2% Gross IRR / 1.0x MIC inclusive of bridge financings. Second: cross-vintage IRR mutation for the same fund. Lexington Capital Partners IX displayed at 16% Net IRR in the 2019 LCP IX marketing tile and 72.3% Net IRR in the 2022 LCP X marketing tile — a 56 percentage point change for the same fund across vintage marketings. Lexington later acknowledged the 72.3% as not meaningful due to revolving credit facility usage; the 2019 tile contained no analogous credit facility disclosure. Both findings represent material distortions of historical track record information that investors cannot detect without methodology footnote excavation.

The regulatory structure is real but multi-layered. US offerings are filed under Regulation D 506(b) — standard private placement exemption, no SEC pre-clearance. Moonfare Securities USA LLC is FINRA-licensed (CRD 325838, approved January 2024) and provides FINRA arbitration jurisdiction for BD-related disputes. The captive BD has no customer fund custody and no direct employees; it is a regulatory presence rather than substantive operation. Luxembourg SCSp feeders operate under AIFMD via Pandomus AIFM. Moonfare GmbH (Germany) operates as a tied agent under DHD GmbH's BaFin license. Investor recourse channels vary by issue: FINRA arbitration for BD disputes; Luxembourg courts for SCSp disputes; Delaware courts for US LP wrapper disputes. No SIPC protection on LP interests.

Semi-annual digital auction with Lexington Partners as institutional backstop buyer. Auction windows are limited (twice per year); between windows the secondary market is closed. Pricing is NAV-referenced but discount-to-NAV is auction-determined — discounts can be material depending on Lexington's bidding capacity and overall auction supply/demand. Liquidity is explicitly not guaranteed. The Moonfare Secondary Fund SCSp is a separate vehicle providing indirect secondaries exposure with semi-liquid structure. Treat the auction as optionality enhancement rather than liquidity guarantee. Investors should plan for full 10-12 year lockup with auction-based optionality between maturities.

This review is specifically scoped to Moonfare's US-facing business — approximately 10% of the platform's claimed €3.9B global AUM. The dominant Moonfare book flows through Moonfare GmbH's German tied-agent structure under BaFin/MiFID, which has different regulatory framework than US Reg D 506(b). The structural catalog analysis applies similarly to EU offerings since the underlying GP marketing materials and Luxembourg SCSp feeder mechanics are the same. The captive US BD analysis and US user access experience apply specifically to US investors.

Because the GPs being legitimate makes the structural disclosure issues more material, not less. Investors evaluating Moonfare are not evaluating KKR or EQT or Carlyle — they have already decided those institutional GPs are credible. They are evaluating Moonfare's product layer: catalog presentation, curation quality, fee structure, access mechanism, regulatory wrapper. The Moonfare value proposition is curation plus ticket aggregation. The disclosure-quality issues documented are not GP-level findings — the underlying GPs provide fuller institutional materials through PPMs and LP reporting; the issue here is the Moonfare presentation layer where institutional GP marketing materials are surfaced as catalog tiles without consistent flagging of methodology choices that materially affect comparability. AltStreet's standard for platform reviews is whether the platform delivers on what it promises. Moonfare promises curation, access, and disclosure-quality wrap on institutional GP funds. The institutional GP access is real. The disclosure-quality wrap is partial by AltStreet's measure. The access mechanism (data room) did not unlock in AltStreet's single verified test. The review reflects this evidence base.

Five steps: (1) Validate independently that the 'Complete your profile' data room actually resolves and contains the underlying GP PPM, KID, and performance history for the specific fund you are considering and for your own account. AltStreet's single verified test did not resolve as documented — your own access may, but verify rather than assume. (2) Read the underlying GP PPM directly — do not rely on the Moonfare catalog tile content. (3) For funds with documented disclosure issues (Ares COF VI, HIG Europe MM LBO Fund I, CVC Growth Partners II, Lexington LCP IX/X, Apax X, Warburg Pincus XIII), validate predecessor performance and methodology against the underlying GP's institutional disclosure. (4) Size positions for full 10-12 year lockup with Lexington auction as optionality not exit guarantee. (5) Plan for Q2-Q3 K-1 delivery, budget tax extension as default, verify UBTI exposure for tax-exempt accounts. Treat Moonfare as a ticket-aggregation and presentation layer — not a substitute for reading the underlying GP PPM, verifying the fee stack, checking methodology footnotes, planning for K-1 delays, and assuming a full 10-12 year lockup.